Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of INARCTICA (Russian Aquaculture) approved dividends for 3 months 2023

6/30/23 AQUA

VSMPO-AVISMA has launched a production complex in the Urals

6/30/23 VSMO

Shareholders of Chelyabinsk Press-Forging Plant approved dividends for 2022

6/30/23 CHKZ

Shareholders of Bashinformsvyaz approved dividends for 2022

6/30/23 BISVP

Shareholders of Saratov oil refinery plant approved dividends for 2022

6/30/23 KRKN

Whoosh services are used by one in four residents of cities where it operates

6/30/23 WUSH

Shareholders of Kuznetskiy Bank approved dividends for 2022

6/30/23 KUZB

Shareholders of Surgutneftegaz approved dividends for 2022

6/30/23 SNGS

Shareholders of Samaraenergo approved dividends for 2023

6/30/23 SAGO

MKB will focus on corporate clients

6/30/23 CBOM